Last month, Laidlaw analyst
Yale Jenhosted a KOL call with the Pulmonary Medicine Chairperson from the Cleveland Clinic. During the call, the need for the treatment of pulmonary sarcoidosis (PS) and how the disease progresses, were highlighted. According to the expert, the cumulative risk of metabolic complications due to the long-term use of glucocorticosteroids stands as the major unmet need. Therefore, the analyst stated that “aTyr has a therapy, ATYR1923, in PS with Phase II trial data on-track for 3Q21.”
According to Jen, besides an accurate safety profile, if ATYR1923 is successful in reducing steroid usage versus the placebo group, along with managing symptoms, including shortness of breath or coughing, it would be a catalyst for aTyr.
The analyst maintained a Buy rating and a price target of $18 (293% upside potential) on the stock “to reflect the potential success of the two first-in-class novel cancer therapeutics.”
“With multiple major catalysts within the next 12 months,” he believes “LIFE shares remain undervalued.”
Consensus among analysts is a Strong Buy based on 4 unanimous Buys. The
average aTyr price targetstands at $14 and implies upside potential of 205.7% to current levels. Shares have gained 12.8% over the past year.